NextCell Pharma AB

NXTCL · Nasdaq Stockholm · Healthcare

1.04SEK −5.3%last day

Price as of 2 October 2026

The price over the past year, with dividends: +9.5%

Performance

1 month

−5.5%

1 year

+9.5%

3 years, per year

−31.0%

5 years, per year

−40.1%

Largest fall, 3 years

−94.0%

Below the peak now

−96.1%

Volatility, 1 year

95.3%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

2.7

Dividend yield

0.0%

Return on equity

−94.5%

Net margin

–

Market value

13 m USD

Quality, value and trend

Where NextCell Pharma stands against every Nordic stock today. 100 is best.

Quality72

Profitability and a sound balance sheet over time. Better than 72% of Nordic stocks.

Value7

The price measured against earnings, assets and cash flow. Better than 7% of Nordic stocks.

Trend50

The price development over the past year. Better than 50% of Nordic stocks.

Combined35

Quality, value and trend together. Better than 35% of Nordic stocks.

About NextCell Pharma

NextCell Pharma AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 24 employees.

NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes. The company also operates Cellaviva, a stem cell bank; and QVance, the first dedicated provider of quality services for developers of advanced therapies. The company was incorporated in 2014 and is headquartered in Huddinge, Sweden.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis